The antiepileptic drug mephobarbital is not transported by P-glycoprotein or multidrug resistance protein 1 at the blood-brain barrier: A positron emission tomography study

Epilepsy Research

Volumn 100, Issue 1-2, 2012, Pages 93-103

  Mairinger, Severin ^a,b,c   Bankstahl, Jens P ^d,e   Kuntner, Claudia ^a   Römermann, Kerstin ^d   Bankstahl, Marion ^d   Wanek, Thomas ^a   Stanek, Johann ^a,c   Löscher, Wolfgang ^d   Müller, Markus ^c   Erker, Thomas ^b   Langer, Oliver ^a,c  

^a AIT AUSTRIAN INSTITUTE OF TECHNOLOGY   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

11C Mephobarbital; Blood brain barrier; Drug resistance; Epilepsy; P glycoprotein; PET

Indexed keywords

CARBON 11; GLYCOPROTEIN P; METHYLPHENOBARBITAL; MULTIDRUG RESISTANCE PROTEIN 1; TARIQUIDAR; TRACER; VERLUKAST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG RETENTION; DRUG STRUCTURE; DRUG TRANSPORT; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PLASMA PROTEIN BINDING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; WILD TYPE;

ANIMALS; ANTICONVULSANTS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; FEMALE; HUMANS; LLC-PK1 CELLS; MEPHOBARBITAL; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; P-GLYCOPROTEINS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; SWINE;

EID: 84863413043     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2012.01.012     Document Type: Article

References (31)

1. 11C]verapamil in epilepsy patients. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:116-123.
2. Baltes S., Fedrowitz M., Tortós C.L., Potschka H., Löscher W. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J. Pharmacol. Exp. Ther. 2007, 320(1):331-343.
3. Baltes S., Gastens A.M., Fedrowitz M., Potschka H., Kaever V., Löscher W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 2007, 52(2):333-346.
4. Bankstahl J.P., Löscher W. Resistance to antiepileptic drugs and expression of P-glycoprotein in two rat models of status epilepticus. Epilepsy Res. 2008, 82(1):70-85.
5. Bankstahl J.P., Bankstahl M., Kuntner C., Stanek J., Wanek T., Meier M., Ding X., Müller M., Langer O., Löscher W. A novel PET imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier. J. Neurosci. 2011, 31(24):8803-8811.
6. 11C-labeled diphenylhydantoin: positron emission tomography in humans. Neurology 1983, 33(5):580-585.
7. Brandt C., Bethmann K., Gastens A.M., Löscher W. The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol. Dis. 2006, 24(1):202-211.
8. Butler T.C., Mahaffee D., Mahaffee C. The role of the liver in the metabolic disposition of mephobarbital. J. Pharmacol. Exp. Ther. 1952, 106(3):364-369.
9. Dallas S., Zhu X., Baruchel S., Schlichter L., Bendayan R. Functional expression of the multidrug resistance protein 1 in microglia. J. Pharmacol. Exp. Ther. 2003, 307(1):282-290.
10. Fox E., Bates S.E. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev. Anticancer Ther. 2007, 7(4):447-459.
11. Hammarlund-Udenaes M., Friden M., Syvänen S., Gupta A. On the rate and extent of drug delivery to the brain. Pharm. Res. 2008, 25(8):1737-1750.
12. 11C]methyl triflate. Appl. Radiat. Isot. 1992, 43:1383-1385.
13. Kannan P., John C., Zoghbi S.S., Halldin C., Gottesman M.M., Innis R.B., Hall M.D. Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin. Pharmacol. Ther. 2009, 86(4):368-377.
14. 11C]verapamil PET. Eur. J. Nucl. Med. Mol. Imaging 2010, 37(5):942-953.
15. 11C]methane. Appl. Radiat. Isot. 1997, 48(2):153-157.
16. Löscher W., Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci. 2005, 6(8):591-602.
17. Löscher W., Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog. Neurobiol. 2005, 76(1):22-76.
18. Löscher W., Luna-Tortós C., Romermann K., Fedrowitz M. Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected. Curr. Pharm. Des. 2011, 17(26):2808-2828.
19. Luna-Tortós C., Fedrowitz M., Löscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 2008, 55(8):1364-1375.
20. Luna-Tortós C., Fedrowitz M., Löscher W. Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology 2010, 58(7):1019-1032.
21. Mairinger S., Erker T., Müller M., Langer O. PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo. Curr. Drug Metab. 2011, 12(5):774-792.
22. Margolskee D.J. Clinical experience with MK-571. A potent and specific LTD4 receptor antagonist. Ann. N. Y. Acad. Sci. 1991, 629:148-156.
23. Matsson P., Pedersen J.M., Norinder U., Bergström C.A., Artursson P. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm. Res. 2009, 26(8):1816-1831.
24. Potschka H., Fedrowitz M., Löscher W. P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci. Lett. 2002, 327(3):173-176.
25. Regesta G., Tanganelli P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res. 1999, 34(2-3):109-122.
26. Remy S., Beck H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain 2006, 129(Pt. 1):18-35.
27. Roeda D., Westera G. The synthesis of some C-11-labeled anti-epileptic drugs with potential utility as radiopharmaceuticals - hydantoins and barbiturates. Int. J. Appl. Radiat. Isot. 1981, 32(11):843-845.
28. van Vliet E.A., van Schaik R., Edelbroek P.M., Redeker S., Aronica E., Wadman W.J., Marchi N., Vezzani A., Gorter J.A. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 2006, 47(4):672-680.
29. 11C-verapamil and PET. J. Nucl. Med. 2009, 50(12):1954-1961.
30. Zhang C., Kwan P., Zuo Z., Baum L. In vitro concentration dependent transport of phenytoin and phenobarbital, but not ethosuximide, by human P-glycoprotein. Life Sci. 2010, 86(23-24):899-905.
31. Zhang C., Zuo Z., Kwan P., Baum L. In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Epilepsia 2011, 52(10):1894-1904.